Table 2 Comparison of baseline clinical, echocardiographic, laboratory and procedural variables between patients with and without AF recurrence after 6 months
No AF recurrence | AF recurrence | |
|---|---|---|
n=55 | n=12 | |
Age (years) | 59 ± 11 | 61 ± 12 |
Males (%) | 63 | 75 |
Paroxysmal AF (%) | 59 | 50 |
Lone AF (%) | 69 | 58 |
AF history (months) | 73 ± 62 | 68 ± 52 |
Body mass index (kg/m2) | 28 ± 4 | 29 ± 5 |
Statins (%) | 26 | 33 |
ACE inhibitor/Angiotensin receptor blocker (%) | 69 | 50 |
LVEF (%) | 60 ± 9 | 56 ± 11 |
LAD (mm) | 43 ± 6 | 45 ± 9 |
Total ablation duration (min) | 35+/−12 * | 61+/−24 * |
Total ablation power (J) | 67.470 ± 23.732* | 117.497 ± 44.058* |
anti-HSP70-antibodies (μg/ml) | 49, 35 – 73 | 47, 37 – 56 |
HSP70 (ng/ml) | 0 [0 – 0] | 0 [0 – 0.29] |
hs-CRP (μg/ml) | 2.08 ± 1.18 | 2.03 ± 0.61 |